This evidence provides the basis for the use of c-Src inhibitors, which are currently available (Dasatinib®), in combination with an agent that blocks ERα function (faslodex/fulvestrant®), as an alternative in the treatment of early-stage BC, with the aim of halting cell progression in the EMT and preventing metastases from forming. This evidence concerns the gene SRC and breast cancer.